NO332754B1 - Anvendelse av en sammensetning av en NMDA-antagonist og en acetylcholine esteraseinhibitor for behandling av Alzheimers sykdom. - Google Patents
Anvendelse av en sammensetning av en NMDA-antagonist og en acetylcholine esteraseinhibitor for behandling av Alzheimers sykdom. Download PDFInfo
- Publication number
- NO332754B1 NO332754B1 NO20045434A NO20045434A NO332754B1 NO 332754 B1 NO332754 B1 NO 332754B1 NO 20045434 A NO20045434 A NO 20045434A NO 20045434 A NO20045434 A NO 20045434A NO 332754 B1 NO332754 B1 NO 332754B1
- Authority
- NO
- Norway
- Prior art keywords
- disease
- treatment
- alzheimer
- nmda antagonist
- composition
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 20
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title claims description 8
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title abstract description 12
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 206010012289 Dementia Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 8
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 5
- 229960004640 memantine Drugs 0.000 claims description 5
- 229960003530 donepezil Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38446702P | 2002-05-31 | 2002-05-31 | |
| DKPA200200844 | 2002-05-31 | ||
| PCT/DK2003/000342 WO2003101458A1 (en) | 2002-05-31 | 2003-05-22 | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20045434L NO20045434L (no) | 2004-12-13 |
| NO332754B1 true NO332754B1 (no) | 2013-01-07 |
Family
ID=29713304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045434A NO332754B1 (no) | 2002-05-31 | 2004-12-13 | Anvendelse av en sammensetning av en NMDA-antagonist og en acetylcholine esteraseinhibitor for behandling av Alzheimers sykdom. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1509232B1 (es) |
| JP (1) | JP2005528431A (es) |
| AT (1) | ATE414519T1 (es) |
| AU (1) | AU2003227516B2 (es) |
| BR (1) | BR0311375A (es) |
| CY (1) | CY1108725T1 (es) |
| DE (1) | DE60324788D1 (es) |
| DK (1) | DK1509232T3 (es) |
| ES (1) | ES2314200T3 (es) |
| IL (1) | IL165255A0 (es) |
| MX (1) | MXPA04011762A (es) |
| NO (1) | NO332754B1 (es) |
| NZ (1) | NZ536603A (es) |
| PL (1) | PL373903A1 (es) |
| PT (1) | PT1509232E (es) |
| SI (1) | SI1509232T1 (es) |
| WO (1) | WO2003101458A1 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200418446A (en) * | 2002-10-24 | 2004-10-01 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| US20060020042A1 (en) * | 2004-01-05 | 2006-01-26 | Forest Laboratories, Inc. | Memantine for the treatment of mild and mild to moderate Alzheimer's disease |
| AU2005205882A1 (en) * | 2004-01-22 | 2005-08-04 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| JP2007529556A (ja) * | 2004-03-19 | 2007-10-25 | アクソニクス インコーポレイテッド | 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤 |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| DE05852057T1 (de) * | 2004-11-23 | 2007-11-29 | Neuromolecular Pharmaceuticals Inc., Emeryville | Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt |
| DE602006016934D1 (de) * | 2005-04-06 | 2010-10-28 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
| NZ562120A (en) * | 2005-04-28 | 2010-07-30 | Eisai R&D Man Co Ltd | Composition comprising donepezil and memantine as antidementia agents |
| TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| DK2091948T3 (da) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
| CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| AU2010325960C1 (en) | 2009-12-02 | 2015-08-06 | Adamas Pharma, Llc | Amantadine compositions and methods of use |
| EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| AU2011276036B2 (en) | 2010-07-05 | 2014-05-22 | Gambro Lundia Ab | An ambulatory ultrafiltration device, related methods and a computer program product |
| TR201007110A2 (tr) | 2010-08-25 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Sinerjik etki gösteren kombinasyonlar |
| WO2012048871A1 (en) | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Memantine for improving cognitive performance in subjects |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| FR2983732B1 (fr) * | 2011-12-09 | 2013-11-22 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent |
| WO2013160728A1 (en) * | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| WO2014035355A1 (en) * | 2012-08-31 | 2014-03-06 | Mahmut Bilgic | Pharmaceutical combination comprising idebenone and memantine |
| WO2014055047A1 (en) * | 2012-08-31 | 2014-04-10 | Mahmut Bilgic | Combination of idebenone and donezepil |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| CN104853755B (zh) * | 2012-12-13 | 2017-08-22 | H.隆德贝克有限公司 | 包含沃替西汀和多奈哌齐的组合物 |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
| US10925834B2 (en) | 2015-05-22 | 2021-02-23 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| WO2017199070A1 (en) * | 2016-05-18 | 2017-11-23 | Suven Life Sciences Limited | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| KR101938872B1 (ko) * | 2016-09-30 | 2019-01-16 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
| US20190269627A1 (en) * | 2016-10-28 | 2019-09-05 | Chase Pharmaceuticals Corporation | Memantine combinations and use |
| TR201619184A2 (tr) | 2016-12-22 | 2018-07-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇ |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| DK3843702T3 (da) | 2019-05-31 | 2023-10-09 | Tecnimede Soc Tecnico Medicinal Sa | Fastdosiskombination af memantin og donepezil til øjeblikkelig frigivelse |
-
2003
- 2003-05-22 PL PL03373903A patent/PL373903A1/xx not_active Application Discontinuation
- 2003-05-22 JP JP2004508815A patent/JP2005528431A/ja active Pending
- 2003-05-22 SI SI200331469T patent/SI1509232T1/sl unknown
- 2003-05-22 BR BR0311375-2A patent/BR0311375A/pt not_active IP Right Cessation
- 2003-05-22 AU AU2003227516A patent/AU2003227516B2/en not_active Ceased
- 2003-05-22 DK DK03724895T patent/DK1509232T3/da active
- 2003-05-22 EP EP03724895A patent/EP1509232B1/en not_active Revoked
- 2003-05-22 MX MXPA04011762A patent/MXPA04011762A/es active IP Right Grant
- 2003-05-22 IL IL16525503A patent/IL165255A0/xx unknown
- 2003-05-22 ES ES03724895T patent/ES2314200T3/es not_active Expired - Lifetime
- 2003-05-22 PT PT03724895T patent/PT1509232E/pt unknown
- 2003-05-22 NZ NZ536603A patent/NZ536603A/en not_active IP Right Cessation
- 2003-05-22 WO PCT/DK2003/000342 patent/WO2003101458A1/en active Application Filing
- 2003-05-22 AT AT03724895T patent/ATE414519T1/de active
- 2003-05-22 DE DE60324788T patent/DE60324788D1/de not_active Expired - Lifetime
-
2004
- 2004-12-13 NO NO20045434A patent/NO332754B1/no not_active IP Right Cessation
-
2009
- 2009-01-21 CY CY20091100080T patent/CY1108725T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2314200T3 (es) | 2009-03-16 |
| AU2003227516A1 (en) | 2003-12-19 |
| BR0311375A (pt) | 2005-03-15 |
| JP2005528431A (ja) | 2005-09-22 |
| IL165255A0 (en) | 2005-12-18 |
| NZ536603A (en) | 2007-06-29 |
| NO20045434L (no) | 2004-12-13 |
| WO2003101458A1 (en) | 2003-12-11 |
| DE60324788D1 (de) | 2009-01-02 |
| CY1108725T1 (el) | 2014-04-09 |
| SI1509232T1 (sl) | 2009-04-30 |
| EP1509232A1 (en) | 2005-03-02 |
| AU2003227516B2 (en) | 2008-03-20 |
| ATE414519T1 (de) | 2008-12-15 |
| PL373903A1 (en) | 2005-09-19 |
| MXPA04011762A (es) | 2005-03-31 |
| DK1509232T3 (da) | 2009-02-23 |
| EP1509232B1 (en) | 2008-11-19 |
| PT1509232E (pt) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO332754B1 (no) | Anvendelse av en sammensetning av en NMDA-antagonist og en acetylcholine esteraseinhibitor for behandling av Alzheimers sykdom. | |
| US20150352107A1 (en) | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions | |
| CA2547639A1 (en) | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists | |
| US20110172251A1 (en) | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
| ZA200507439B (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| US20090203727A1 (en) | Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion | |
| JPS63243028A (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| US3954988A (en) | Use of lisuride and physiologically acceptable salts thereof to achieve psychic energizer effects | |
| CN116940362A (zh) | 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性 | |
| US20120010242A1 (en) | Low dose pipamperone in treating mood disorders | |
| EP1547650A1 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
| EP2236138A1 (en) | Low dose pipamperone in treating mood and anxiety disorders | |
| MX2012014184A (es) | Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta [c] pirrol-2(1h)-il] propoxi} benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen. | |
| WO2010112530A1 (en) | Pipamperone and a second agent in treating mood and anxiety disorders | |
| KR101016927B1 (ko) | 알츠하이머 질환의 치료용 ｎｍｄａ 길항제 및 아세틸콜린에스테라제 억제제의 조합물 | |
| US9877951B2 (en) | Method for treating dementia | |
| CA2451798C (en) | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists | |
| Lawlor et al. | VI. 2.2 Atypical Antipsychotics | |
| NZ604084B2 (en) | New combination between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide and an nmda receptor antagonist, and pharmaceutical compositions containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |
|
| MM1K | Lapsed by not paying the annual fees |